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Introduction
In rheumatoid arthritis (RA), the synovium is character-
ized by hyperplasia of the intimal lining and mononuclear
infiltration of the sublining, leading to erosion of cartilage
and subchondral bone by invasive pannus [1]. Angiogen-
esis plays a crucial role in the formation of pannus, and
the extensive network of blood vessels facilitates recruit-
ment of mononuclear cells [2]. Proangiogenic mediators
found in RA synovial tissue regulate migration and prolif-
eration of endothelial cells. In addition, αvβ3 and αvβ5
integrins are important in angiogenesis [3–5]. αvβ3 is
expressed on synovial blood vessels in rheumatoid arthri-
tis [6,7], and αv antagonists injected directly into the
joint suppress synovitis in rabbits [7]. Therefore, targeted
Abstract
Because angiogenesis plays a major role in the perpetuation of inflammatory arthritis, we explored a
method for selectively targeting and destroying new synovial blood vessels. Mice with collagen-
induced arthritis were injected intravenously with phage expressing an RGD motif. In addition, the
RGD peptide (RGD-4C) was covalently linked to a proapoptotic heptapeptide dimer, D(KLAKLAK)2,
and was systemically administered to mice with collagen-induced arthritis. A phage displaying an
RGD-containing cyclic peptide (RGD-4C) that binds selectively to the αvβ3 and αvβ5 integrins
accumulated in inflamed synovium but not in normal synovium. Homing of RGD-4C phage to inflamed
synovium was inhibited by co-administration of soluble RGD-4C. Intravenous injections of the RGD-
4C–D(KLAKLAK)2 chimeric peptide significantly decreased clinical arthritis and increased apoptosis of
synovial blood vessels, whereas treatment with vehicle or uncoupled mixture of the RGD-4C and the
untargeted proapoptotic peptide had no effect. Targeted apoptosis of synovial neovasculature can
induce apoptosis and suppress clinical arthritis. This form of therapy has potential utility in the
treatment of inflammatory arthritis.
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induction of apoptosis in the neovasculature is a poten-
tial therapy for RA [8].
We evaluated a novel method of targeted drug delivery to
inflamed joints using peptides that selectively bind to neo-
vasculature [9]. Our data show that a constrained cyclic
RGD peptide that binds to αvβ3 and αvβ5 integrins [10]
homes to blood vessels in inflamed synovium after sys-
temic administration. This peptide was covalently linked to
a 14-amino-acid proapoptotic peptide and successfully
suppressed arthritis in collagen-induced arthritis (CIA).
Materials and methods
Phage and peptides
Insertless fd phage and phage presenting the peptide
CDCRGDCFC (RGD-4C) was prepared as previously
described elsewhere [10–12]. The chemical structure of
RGD-4C was determined by NMR analysis and is
described in detail elsewhere [13]. K91kan bacteria were
a gift from G Smith. The peptides RGD-4C, CARAC,
D(KLAKLAKKLAKLAK) [designated D(KLAKLAK)2], and
CDCRGDCFC-GG-D(KLAKLAKKALKLAK) [designated
RGD-4C-D(KLAKLAK)2] were synthesized by AnaSpec,
Inc (San Jose, CA, USA).
Collagen-induced arthritis in mice
CIA was induced in 6- to 8-week-old male DBA/1J mice
(Jackson Laboratory, Bar Harbor, ME, USA), as previously
described [14,15].
Phage delivery and detection
To determine homing characteristics of the RGD-4C
phage in vivo, mice with CIA on day 35 after immunization
were anesthetized and injected with 200 µl of medium con-
taining 1010 transducing units (TU) of phage into the tail
vein. After 5 min, the mice were perfused with 5 ml of
medium given through the right atrium. The organs of inter-
est and synovia were pooled, homogenized, incubated with
K91kan bacteria for 30 min, and plated on tetracycline
plates. Phage enrichment was calculated as the ratio of
TU/g of synovial tissue divided by the TU/g of brain tissue.
Because animals are perfused and sacrificed within
minutes after administration, relative rates of penetration
into the target tissue do not influence this assay system
(i.e., the target is the intravascular surface of the blood
vessels). For the competitive peptide inhibition studies, the
phage was injected with either 1 mg of the RGD-4C
peptide or with 1 mg of a control peptide, CARAC [16].
Unimmunized mice were used as normal controls.
Treatment protocol for CIA
In the clinical efficacy study, mice with established CIA
were anesthetized and injected intravenously on days 35
and 41 with either 500 µg of covalently linked RGD-4C-
D(KLAKLAK)2 dissolved in 500 µl DMEM (N = 14), with a
mixture of the equimolar amounts of uncoupled RGD-4C
and D(KLAKLAK)2 dissolved in 500 µl DMEM (N = 20), or
with 500 µl DMEM only (N = 20). The clinical arthritis
scores were assessed daily in a blinded manner using a
semiquantitative scoring system from 0 to 4+ for each
paw (maximum score) [14,15].
Immunohistochemical staining and antibodies
Mice were sacrificed on day 35 after immunization and their
paws and internal organs were fixed in a 10% formalin solu-
tion for 24 hours, decalcified, and embedded in paraffin.
The primary antibodies (horseradish peroxidase/anti-M13
monoclonal conjugate [Pharmacia Biotech, Piscataway, NJ,
USA], rabbit anti-αv antibody [17]) and secondary antibody
(swine anti-rabbit-AP; Dako, Glostrup, Denmark) were
diluted in 2% BSA–PBS. Peroxidase activity was detected
using 3,3′diaminobenzidine, and alkaline phosphatase activ-
ity was detected using alkaline phosphatase kit III (Vector
Laboratories Inc, Burlingame, CA, USA).
Terminal deoxynucleotidyl transferase-mediated UTP
end labeling (TUNEL) assay
The paws of the animals treated with vehicle or 500 µg of
RGD-4C coupled to D(KLAKLAK)2 were fixed in a 10% for-
malin solution, decalcified for 14 days in a 15% EDTA–PBS
solution at 4°C, and embedded in paraffin. Sections (5 µm)
were incubated with proteinase K (20 µg/ml) for
20 minutes. The In situ Death Detection Kit from Boehringer
Mannheim GmbH (Mannheim, Germany) was used in
accordance with the manufacturer’s instructions.
Results
Phage displaying RGD-4C accumulates in inflamed
synovium
RGD-4C phage was injected intravenously into DBA/1J
mice with active CIA on day 35 (N = 18). Control mice
with CIA received insertless fd phage (N = 14). After cir-
culation of the phage and perfusion with medium, the
control organ (the brain) and synovium from arthritic joints
were surgically dissected and phage enrichment was cal-
culated as the ratio of TU/g of synovial tissue to TU/g of
control tissue. Accumulation of the RGD-4C phage in
inflamed synovium was 8.0 ± 1.7 (mean ± standard devia-
tion) fold that in brain (P < 0.01). For the control phage,
this value was 1.5 ± 0.3 (Fig. 1). Neither the RGD-4C
phage nor the control phage accumulated in synovium of
normal DBA/1J mice (N = 6 and 5, respectively;
P < 0.0001 compared with inflamed synovium). Other
organs (lung, liver, spleen, heart, kidney, pancreas, and
gut) were also tested for enrichment of the RGD-4C and
control phage. There was no selective accumulation of the
RGD-4C phage in these organs (data not shown).
Inhibition of RGD-4C phage by a competing peptide
After showing that the RGD-4C phage targets inflamed
synovium, we assessed the specificity of homing using the
soluble RGD-4C peptide, a competitive inhibitor. TheRGD-4C phage was co-injected with 1 mg of either the
RGD-4C peptide (N = 5) or a control peptide (CARAC;
N = 5). Figure 2 shows that soluble RGD-4C peptide, but
not the control peptide, blocked accumulation of the
RGD-4C phage in inflamed synovium.
RGD-4C-expressing phage and αv co-localize in
synovial blood vessels
The localization of RGD-4C phage in synovium was exam-
ined in more detail by immunohistochemistry. Staining of
paraffin-embedded sections revealed localization of RGD-
4C-expressing phage to small vessels in the sublining of
the inflamed synovium (Fig. 3a). Expression of the inte-
grins containing αv was also observed in the small vessels
in the inflamed synovial sublining (Fig. 3b). Immunohisto-
logic analysis did not reveal phage in the synovium of
normal mice injected with the RGD-4C phage.
Suppression of arthritis by targeted apoptosis of
synovial neovasculature
DBA/1J mice with CIA were administered a chimeric com-
pound consisting of the peptide RGD-4C covalently linked
to the proapoptotic peptide D(KLAKLAK)2 [16]. The
chimeric compound was injected intravenously on days 35
and 41. Control mice with CIA were either injected with
the vehicle or were co-injected with similar quantities of
the uncoupled RGD-4C and D(KLAKLAK)2 peptides. The
mean pretreatment score was 10.3 ± 0.5. Neither the
vehicle nor the uncoupled mixture of RGD-4C with
D(KLAKLAK)2 had no effect on arthritis, whereas the tar-
geted chimeric compound significantly decreased clinical
arthritis on day 44 (P < 0.001; Fig. 4).
TUNEL studies were performed on joint specimens col-
lected 72 hours after intravenous injection of the chimeric
peptide. Abundant positive cells were detected in small
vessels of the inflamed synovium (Fig. 3c) but not in syn-
ovium of arthritic mice injected with vehicle (not shown).
Positive cells were not found in lung, liver, or spleen of
chimera-treated arthritic mice, indicating that apoptosis
was selective to inflamed synovium.
Discussion
Angiogenesis has been implicated in inflammatory dis-
eases such as RA [2,8]. Synovial tissues from patients
with RA express more of the angiogenesis marker, αvβ3
integrin, than control synovium [6,7,18]. An angiostatic
compound suppressed arthritis in rat adjuvant arthritis and
CIA [19,20], and intra-articular administration of an RGD
peptide that binds to αvβ3 decreased synovial inflamma-
tion in a rabbit model of arthritis [7].
The homing properties of the cyclic RGD peptide allowed
us to deliver a toxic agent – the proaptotic peptide
D(KLAKLAK)2 – to the synovial microvasculature through
systemic administration. Homing minimized systemic toxic-
ity in this model, as has been found in experimental tumor
treatments [9,16]. Systemic treatment with RGD peptides
that are selective for αvβ3 reduces angiogenesis, presum-
ably by blocking the function of the integrin [21]. However,
the systemic administration of free RGD-4C peptide had
no effect on arthritis, indicating that the RGD-4C merely
acts to target the proapoptotic peptide.
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Figure 1
Phage homing to inflamed synovium. DBA/1J mice with (‘inflamed’)
and without (‘normal’) collagen-induced arthritis were injected
intravenously on day 35 with 1010 transducing units (TU) of phage
expressing RGD-4C on their surface and control phage. Phage
enrichment was calculated as the ratio of TU/g in synovial tissue to
TU/g in brain tissue. RGD-4C phage accumulate in inflamed synovium,
but not in normal synovium (P < 0.0001).
Figure 2
Inhibition of RGD-4C phage homing with the cognate soluble peptide.
In competitive peptide inhibition studies in mice with collagen-induced
arthritis, RGD-4C phage (‘RGD phage’) was co-injected with 1 mg of
either RGD-4C peptide or control peptide (CARAC). Note
accumulation of RGD-4C phage in inflamed synovium (P < 0.01).The RGD-4C peptide also enhances internalization of
RGD-4C– D(KLAKLAK)2 [9]. When covalently linked to the
homing peptide RGD-4C, the proapoptotic peptide enters
cells that express αvβ3 or αvβ5 [22]. Once in the cyto-
plasm, it disrupts mitochondrial membranes and initiates
apoptosis [15]. Distribution studies in vivo followed by cell
fractionation indicate that RGD-4C–D(KLAKLAK)2 localizes
to mitochondrial membranes of the target cells but not to
endothelial cells in control tissues [15]. Cells that do not
express these integrins are spared, because the proapop-
totic peptide alone is not internalized. As with our studies,
Pasqualini and colleagues showed that αv-directed RGD-
4C phage is not detected in normal tissues, but accumu-
lates on the surface of tumor blood vessels [23].
Intravenous treatment of mice with established arthritis
using RGD-4C–D(KLAKLAK)2 induced apoptosis of
endothelial cells in the inflamed synovium. This was asso-
ciated with decreased severity of arthritis compared with
untreated mice or mice treated with a mixture of uncou-
pled RGD-4C and D(KLAKLAK)2 peptides. Since we did
not observe systemic toxicity and did not find apoptotic
cells in other tissues besides the inflamed synovium,
RGD-4C–D(KLAKLAK)2 appears to have a favorable phar-
macological profile.
These data support the feasibility of administering sys-
temic agents that home to sites of inflammation as a
means of delivering a therapeutic agent. This approach
can treat multiple sites simultaneously while not accumu-
lating in normal tissues. Our study is the first example of
selective proapoptotic treatment of an inflammatory
disease using homing peptides and could potentially be
used to deliver therapeutic agents to inflamed joints.
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Figure 3
Detection of RGD-4C-phage, αvβ3, and TUNEL positive cells in
synovial blood vessels. Mice with established collagen-induced arthritis
were injected with RGD-4C and sections were stained for (a) phage
(blue blood vessels, denoted here by arrows) or (b) αvβ3 (brown blood
vessels, denoted here by arrows) by immunohistochemistry. In a
second experiment, mice with collagen-induced arthritis were given
RGD-4C–D(KLAKLAK)2 on day 35 and TUNEL assays were performed
on day 38. Positive cells were found in sublining vessels of inflamed
synovium in the animals treated with RGD-4C–D(KLAKLAK)2 (arrows)
(c) but not in the control animals (not shown).
Figure 4
Changes in clinical arthritis scores in mice with collagen-induced
arthritis after treatment with peptides or the vehicle. Mice were injected
intravenously on days 35 and 41 with either the targeted proapoptotic
chimeric peptide RGD-4C–D(KLAKLAK)2 or a mixture of the uncoupled
peptides RGD-4C and D(KLAKLAK)2 or the vehicle. Clinical arthritis
scores were evaluated using a scale of 0 to 4+ for each paw
(maximum = 16). The mean pretreatment score was 10.3 ± 0.5.References
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